Drug Profile
Monomeric DAPTA
Alternative Names: Adaptavir; mDAPTA; Monomeric (D-Alanine1) Peptide T amide; RAP-101Latest Information Update: 28 May 2019
Price :
$50
*
At a glance
- Originator RAPID Pharmaceuticals
- Class Anti-inflammatories; Antipsoriatics; Antivirals; Peptides; Small molecules
- Mechanism of Action CCR5 receptor antagonists; HIV fusion inhibitors; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hepatitis B; HIV infections; Progressive multifocal leukoencephalopathy
Most Recent Events
- 28 May 2019 No recent reports of development identified for phase-I development in Progressive multifocal leukoencephalopathy in USA (Intranasal, Spray)
- 24 Sep 2015 No recent reports on development identified - Phase-II for HIV infections in USA (Intranasal)
- 21 Mar 2011 Efficacy data from a Phase-II trial in HIV infections released by RAPID Pharmaceuticals